Breaking News

Purdue Pharma, Medidata Expand Enterprise Agreement

February 25, 2013

Broadens cloud-based solutions for clinical trial operational efficiencies

Purdue Pharma has signed a multi-year enterprise agreement expanding its use of Medidata’s cloud-based solutions aimed at further improving clinical trial operational efficiencies, resource savings and decision making. Purdue is also renewing the Medidata applications it currently uses across its portfolio of treatments for pain, sleep and gastrointestinal disorders, including Medidata Designer and EDC and management system, Medidata Rave.
 
Purdue has also adopted Medidata’s clinical trial management system (CTMS) and is now adding clinical business analytics with Medidata Insights, including its site quality management module, as well as support for risk-based monitoring with Rave Targeted SDV and additional modules of the site budgeting and financial management tool Medidata Grants Manager.
 
“After seeing the results we were able to achieve with Medidata’s Clinical Cloud, we have enthusiastically embraced a number of new capabilities,” said Charles Willmer, senior director of clinical systems, Purdue. “Expanding our use of Medidata’s platform will enable us to reduce cost, complexity and time in site negotiation and monitoring, track CRO activities more efficiently, and improve visibility into study performance.”
 
“As a leader in its industry, Purdue is aggressively developing a holistic and integrated clinical research technology strategy, and with this approach will be better positioned to evolve and strengthen its R&D operations,” said Tarek Sherif, chairman and chief executive officer, Medidata Solutions. “Our cloud-based solution is enabling Purdue to focus on innovation of new therapies while reducing clinical development costs, speeding trials and improving decision making.”

Related Compliance:

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks

  • The Growing Realm of Real-World Data

    Kristin Brooks, Contract Pharma||November 8, 2016
    PPD's Evidera acquisition aims to help clients address the growing demand for evidence from regulators and payers

  • Mastering Immunotherapy Clinical Trials: Dosing and Response

    Mastering Immunotherapy Clinical Trials: Dosing and Response

    Kristin Brooks, Contract Pharma||August 1, 2016
    Andrew Zupnick of Novella Clinical provides insights into dosing and measuring response in immunotherapy clinical trials